KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

How bilastine is used to treat allergic rhinitis and urticaria in children.

Pablo Rodríguez Del Río, Fernando Rodríguez Fernández, Esther Ballester Asensio, Miguel Tortajada-Girbés

Immunotherapy 14(1) 77-89

PMID34850647
PMCID-
DOI10.2217/imt-2021-0251
发表日期2021-12-01
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Management guidelines for allergic rhinitis and urticaria recommend oral second-generation antihistamines as first-line treatment. The efficacy and safety of bilastine, the newest nonsedating second-generation antihistamine, are well established in adolescents/adults with these allergic conditions. The bilastine development program for pediatric use (2-<12 years) followed EMA-authorized processes. Pharmacokinetic/pharmacodynamic simulation and modeling and a pharmacokinetic study were conducted to identify and confirm the pediatric dose (10 mg/day). A Phase III, multicenter, double-blind, randomized, placebo-controlled, parallel-group study was performed to confirm the safety of bilastine 10 mg/day in children. In this article, evidence is reviewed for use of bilastine in children with allergic rhinoconjunctivitis or urticaria. Several cases are presented which demonstrate its role in routine clinical practice.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。